137,430 Shares in Contineum Therapeutics, Inc. $CTNM Acquired by Monashee Investment Management LLC

Monashee Investment Management LLC acquired a new position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 137,430 shares of the company’s stock, valued at approximately $1,571,000.

A number of other hedge funds have also recently added to or reduced their stakes in CTNM. Dynamic Technology Lab Private Ltd acquired a new position in Contineum Therapeutics in the first quarter worth approximately $118,000. Strs Ohio acquired a new position in Contineum Therapeutics in the first quarter worth approximately $27,000. Norges Bank acquired a new position in Contineum Therapeutics in the second quarter worth approximately $674,000. Qube Research & Technologies Ltd acquired a new position in Contineum Therapeutics in the second quarter worth approximately $43,000. Finally, Jane Street Group LLC acquired a new position in Contineum Therapeutics in the second quarter worth approximately $81,000.

Contineum Therapeutics Stock Up 5.0%

Shares of CTNM stock opened at $11.86 on Friday. Contineum Therapeutics, Inc. has a 12 month low of $3.57 and a 12 month high of $16.33. The business’s 50 day moving average is $13.13 and its two-hundred day moving average is $12.94. The company has a market cap of $443.45 million, a PE ratio of -6.08 and a beta of 0.89.

Contineum Therapeutics (NASDAQ:CTNM) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.16. As a group, equities analysts expect that Contineum Therapeutics, Inc. will post -1.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CTNM has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Monday, April 20th. Morgan Stanley increased their price objective on Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Wall Street Zen upgraded Contineum Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Robert W. Baird increased their price target on Contineum Therapeutics from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Friday, March 6th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.